1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Cryptosporidiosis - Pipeline Review, H1 2016

Cryptosporidiosis - Pipeline Review, H1 2016

  • May 2016
  • -
  • Global Markets Direct
  • -
  • 28 pages

Cryptosporidiosis - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Cryptosporidiosis - Pipeline Review, H1 2016’, provides an overview of the Cryptosporidiosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cryptosporidiosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cryptosporidiosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cryptosporidiosis
- The report reviews pipeline therapeutics for Cryptosporidiosis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Cryptosporidiosis therapeutics and enlists all their major and minor projects
- The report assesses Cryptosporidiosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Cryptosporidiosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Cryptosporidiosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cryptosporidiosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Cryptosporidiosis - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Cryptosporidiosis Overview 5
Therapeutics Development 6
Pipeline Products for Cryptosporidiosis - Overview 6
Pipeline Products for Cryptosporidiosis - Comparative Analysis 7
Cryptosporidiosis - Therapeutics under Development by Companies 8
Cryptosporidiosis - Therapeutics under Investigation by Universities/Institutes 9
Cryptosporidiosis - Pipeline Products Glance 10
Early Stage Products 10
Cryptosporidiosis - Products under Development by Companies 11
Cryptosporidiosis - Products under Investigation by Universities/Institutes 12
Cryptosporidiosis - Companies Involved in Therapeutics Development 13
Dafra Pharma International Ltd. 13
ioGenetics, Inc. 14
Romark Laboratories, L.C. 15
Cryptosporidiosis - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Target 17
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Cryptosporidiosis - Dormant Projects 25
Cryptosporidiosis - Discontinued Products 26
Appendix 27
Methodology 27
Coverage 27
Secondary Research 27
Primary Research 27
Expert Panel Validation 27
Contact Us 27
Disclaimer 28

List of Tables
Number of Products under Development for Cryptosporidiosis, H1 2016 6
Number of Products under Development for Cryptosporidiosis - Comparative Analysis, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Number of Products under Investigation by Universities/Institutes, H1 2016 9
Comparative Analysis by Early Stage Development, H1 2016 10
Products under Development by Companies, H1 2016 11
Products under Investigation by Universities/Institutes, H1 2016 12
Cryptosporidiosis - Pipeline by Dafra Pharma International Ltd., H1 2016 13
Cryptosporidiosis - Pipeline by ioGenetics, Inc., H1 2016 14
Cryptosporidiosis - Pipeline by Romark Laboratories, L.C., H1 2016 15
Assessment by Monotherapy Products, H1 2016 16
Number of Products by Stage and Target, H1 2016 18
Number of Products by Stage and Mechanism of Action, H1 2016 20
Number of Products by Stage and Route of Administration, H1 2016 22
Number of Products by Stage and Molecule Type, H1 2016 24
Cryptosporidiosis - Dormant Projects, H1 2016 25
Cryptosporidiosis - Discontinued Products, H1 2016 26

List of Figures
Number of Products under Development for Cryptosporidiosis, H1 2016 6
Number of Products under Development for Cryptosporidiosis - Comparative Analysis, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Number of Products under Investigation by Universities/Institutes, H1 2016 9
Comparative Analysis by Early Stage Products, H1 2016 10
Assessment by Monotherapy Products, H1 2016 16
Number of Products by Targets, H1 2016 17
Number of Products by Stage and Targets, H1 2016 17
Number of Products by Mechanism of Actions, H1 2016 19
Number of Products by Stage and Mechanism of Actions, H1 2016 19
Number of Products by Routes of Administration, H1 2016 21
Number of Products by Stage and Routes of Administration, H1 2016 21
Number of Products by Molecule Types, H1 2016 23
Number of Products by Stage and Top 10 Molecule Types, H1 2016 23

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,000 pages and 550 tables, and provides granular data and analysis not available from any other published source. The survey is designed ...


Download Unlimited Documents from Trusted Public Sources

Infectious Disease Statistics in the US

  • December 2016
    32 pages
  • Infectious Dise...  

    Asthma  

  • United States  

View report >

Infectious Disease Statistics in Africa

  • December 2016
    3 pages
  • Infectious Dise...  

    Therapy  

    Pharmaceutical  

  • Africa  

    World  

View report >

Infectious Disease Statistics in Brazil

  • December 2016
    9 pages
  • Infectious Dise...  

    Hospital  

  • Brazil  

View report >

Related Market Segments :

Infectious Disease
Therapy

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.